Ozempic maker Novo Nordisk failed to disclose more payments made to healthcare groups - watchdog

The company behind popular weight-loss drugs failed to disclose even more money it paid to healthcare groups and patient organisations , a pharmaceutical watchdog has said.

The full article is no longer available.